Resources

Reccomendations for Improving Support for NOMSD and MOGAD Care

EMSP provides advocacy and support for people with MOGAD and NMOSD, recognising that these are separate autoimmune conditions requiring distinct treatment approaches. 

Dana and Jiri session

Eva Kubala Havrdová

Evidence-Based Strategies for Managing Multiple Sclerosis Fatigue

Fatigue is one of the most challenging and pervasive symptoms experienced by people living with Multiple Sclerosis (MS). According to the Impact of Symptoms of Multiple Sclerosis study, chronic fatigue stands as the most commonly reported symptom, with 54% of people with MS experiencing it almost continuously.

EMSP Annual Report 2024

The European Multiple Sclerosis Platform presents our 2024 Annual Report, documenting a year of significant achievements in our mission to improve the quality of life for people affected by Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (MOGAD) throughout Europe.

EMSP Annual Report 2023

We hope you will enjoy reading our EMSP Annual Report 2023 in a downloadable PDF format with a summary of activities and achievements.